Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yi Shanfu is a pharmaceutical drug, a brand name for Polyene Phosphatidylcholine Capsules. It is primarily used for the auxiliary improvement of various liver conditions, including toxic liver damage (e.g., liver damage caused by drugs, toxins, chemicals, and alcohol), fatty liver, and hepatitis. It also addresses associated symptoms such as loss of appetite and right upper abdominal pressure. The drug functions by delivering high-dose, readily absorbed polyene phosphatidylcholine, which is structurally similar to essential endogenous phospholipids. These molecules integrate into liver cell and organelle membranes, thereby aiding in the normalization of impaired liver function and enzyme activity, regulating the liver's energy balance, fostering liver tissue regeneration, facilitating the conversion of neutral fats and cholesterol into more metabolizable forms, and stabilizing bile. Additionally, it contributes to accelerating membrane regeneration and stabilization, inhibiting lipid peroxidation, and suppressing collagen synthesis. The drug is manufactured by Sanofi (Beijing) Pharmaceutical Co., Ltd.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yi Shanfu.